Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii

Vaccine

Volumn 28, Issue 29, 2010, Pages 4644-4652

  Stoyanov, Cristina T ^a   Boscardin, Silvia B ^a   Deroubaix, Stephanie ^a   Barba Spaeth, Giovanna ^a   Franco, David ^a   Nussenzweig, Ruth S ^b   Nussenzweig, Michel ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malaria; Protection; YF17D

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; RECOMBINANT YELLOW FEVER VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN BHK; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SPOROZOITE; VIRUS RECOMBINANT;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMIDS; PLASMODIUM YOELII; PROTOZOAN PROTEINS; VACCINES, ATTENUATED; YELLOW FEVER VACCINE;

EID: 77953122920     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.071     Document Type: Article

References (52)

1. Nussenzweig R.S., Vanderberg J.P., Most H., and Orton C. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 222 May (5192) (1969) 488-489
2. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24 May (3) (1975) 397-401
3. Nussenzweig V., and Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 45 (1989) 283-334
4. Singh A.P., Buscaglia C.A., Wang Q., Levay A., Nussenzweig D.R., Walker J.R., et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131 November (3) (2007) 492-504
5. Frevert U., Sinnis P., Cerami C., Shreffler W., Takacs B., and Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 177 May (5) (1993) 1287-1298
6. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 January (2) (1997) 86-91
7. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS. S malaria vaccine. J Infect Dis 178 October (4) (1998) 1139-1144
8. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200 August (3) (2009) 337-346
9. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370 November (9598) (2007) 1543-1551
10. Theiler M., and Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65 (1937) 787-800
11. Lefeuvre A., Marianneau P., and Deubel V. Current Assessment of Yellow Fever and Yellow Fever Vaccine. Curr Infect Dis Rep 6 April (2) (2004) 96-104
12. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203 February (2) (2006) 413-424
13. Barba-Spaeth G., Longman R.S., Albert M.L., and Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202 November (9) (2005) 1179-1184
14. Palmer D.R., Fernandez S., Bisbing J., Peachman K.K., Rao M., Barvir D., et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88 January (Pt 1) (2007) 148-156
15. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vac 2 March-April (2) (2006) 60-67
16. Dean C.H., Alarcon J.B., Waterston A.M., Draper K., Early R., Guirakhoo F., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vac 1 May-June (3) (2005) 106-111
17. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103 April (17) (2006) 6694-6699
18. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78 November (22) (2004) 12497-12507
19. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang Z., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72 January (1) (2005) 74-81
20. Tao D., Barba-Spaeth G., Rai U., Nussenzweig V., Rice C.M., and Nussenzweig R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 201 January (2) (2005) 201-209
21. Rice C.M., Grakoui A., Galler R., and Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1 December (3) (1989) 285-296
22. Hahn C.S., Hahn Y.S., Rice C.M., Lee E., Dalgarno L., Strauss E.G., et al. Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol 198 November (1) (1987) 33-41
23. Boscardin S.B., Hafalla J.C., Masilamani R.F., Kamphorst A.O., Zebroski H.A., Rai U., et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203 March (3) (2006) 599-606
24. Sano G., Hafalla J.C., Morrot A., Abe R., Lafaille J.J., and Zavala F. Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J Exp Med 194 July (2) (2001) 173-180
25. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 February (1) (1999) 77-92
26. Amberg S.M., and Rice C.M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J Virol 73 October (10) (1999) 8083-8094
27. Schlesinger J.J., Walsh E.E., and Brandriss M.W. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J Gen Virol 65 October (Pt 10) (1984) 1637-1644
28. Chambers T.J., McCourt D.W., and Rice C.M. Yellow fever virus proteins NS2A, NS2B, and NS4B: identification and partial N-terminal amino acid sequence analysis. Virology 169 March (1) (1989) 100-109
29. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194 September (6) (2001) 769-779
30. Vaughan K., Blythe M., Greenbaum J., Zhang Q., Peters B., Doolan D.L., et al. Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol 31 February (2) (2009) 78-97
31. Franke E.D., Corradin G., and Hoffman S.L. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J Immunol 159 October (7) (1997) 3424-3433
32. Romero P., Maryanski J.L., Cordey A.S., Corradin G., Nussenzweig R.S., and Zavala F. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol Lett 25 August (1-3) (1990) 27-31
33. Lal A.A., de la Cruz V.F., Welsh J.A., Charoenvit Y., Maloy W.L., and McCutchan T.F. Structure of the gene encoding the circumsporozoite protein of Plasmodium yoelii. A rodent model for examining antimalarial sporozoite vaccines. J Biol Chem 262 March (7) (1987) 2937-2940
34. Weiss W.R., Mellouk S., Houghten R.A., Sedegah M., Kumar S., Good M.F., et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 171 March (3) (1990) 763-773
35. Molenkamp R., Kooi E.A., Lucassen M.A., Greve S., Thijssen J.C., Spaan W.J., et al. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J Virol 77 January (2) (2003) 1644-1648
36. Khromykh A.A., Meka H., Guyatt K.J., and Westaway E.G. Essential role of cyclization sequences in flavivirus RNA replication. J Virol 75 July (14) (2001) 6719-6728
37. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., and Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 February (4) (2006) 1734-1741
38. Bonaldo M.C., Mello S.M., Trindade G.F., Rangel A.A., Duarte A.S., Oliveira P.J., et al. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J 4 (2007) 115
39. Grillot D., Michel M., Muller I., Tougne C., Renia L., Mazier D., et al. Immune responses to defined epitopes of the circumsporozoite protein of the murine malaria parasite, Plasmodium yoelii. Eur J Immunol 20 June (6) (1990) 1215-1222
40. Renia L., Marussig M.S., Grillot D., Pied S., Corradin G., Miltgen F., et al. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc Natl Acad Sci USA 88 September (18) (1991) 7963-7967
41. Del Giudice G., Grillot D., Renia L., Muller I., Corradin G., Louis J.A., et al. Peptide-primed CD4+ cells and malaria sporozoites. Immunol Lett 25 August (1-3) (1990) 59-63
42. Zisman B., Wheelock E.F., and Allison A.C. Role of macrophages and antibody in resistance of mice against yellow fever virus. J Immunol 107 July (1) (1971) 236-243
43. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., and Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330 December (6149) (1987) 664-666
44. Malik A., Egan J.E., Houghten R.A., Sadoff J.C., and Hoffman S.L. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 88 April (8) (1991) 3300-3304
45. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., and Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341 September (6240) (1989) 323-326
46. Weiss W.R., Sedegah M., Beaudoin R.L., Miller L.H., and Good M.F. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85 January (2) (1988) 573-576
47. Renia L., Grillot D., Marussig M., Corradin G., Miltgen F., Lambert P.H., et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 150 February (4) (1993) 1471-1478
48. Othoro C., Moore J.M., Wannemuehler K.A., Moses S., Lal A., Otieno J., et al. Elevated gamma interferon-producing NK cells, CD45RO memory-like T cells, and CD4 T cells are associated with protection against malaria infection in pregnancy. Infect Immun 76 April (4) (2008) 1678-1685
49. Dodoo D., Omer F.M., Todd J., Akanmori B.D., Koram K.A., and Riley E.M. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis 185 April (7) (2002) 971-979
50. D'Ombrain M.C., Robinson L.J., Stanisic D.I., Taraika J., Bernard N., Michon P., et al. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis 47 December (11) (2008) 1380-1387
51. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 179 April (V) (1999) 980-988
52. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361 July (5) (2009) 468-477